GlassScriptPhysician profile
Karie L Prokop
NPI 1447558127
$67,683.23
in general payments reported to CMS, 2019-2025
43 companies · $4,494 in 2025
The $4,494 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16K · 2022: $19K · 2023: $18K · 2024: $10K · 2025: $4,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $6,298 · Travel and Lodging: $2,082 · Education: $64.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,606.25 |
| Food and Beverage | $6,297.90 |
| Travel and Lodging | $2,081.64 |
| Education | $64.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $29,798.09 | 2021-2023 | |
| Abbvie INC. | $17,664.01 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $11,975.69 | 2024-2025 | Zenpep |
| Allergan, INC. | $1,731.96 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,148.10 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $750.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $550.38 | 2022-2025 | Auvelity, Sunosi |
| Phathom Pharmaceuticals, INC. | $538.05 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $485.38 | 2021-2025 | Emgality, Reyvow, Mounjaro |
| Janssen Pharmaceuticals, INC | $325.26 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.20 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.28 | 2021-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $195.16 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $194.69 | 2022-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Esperion Therapeutics, INC. | $164.52 | 2021-2024 | Nexletol |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $160.87 | 2022-2025 | |
| Pfizer INC. | $144.38 | 2022-2025 | |
| Glaxosmithkline, LLC. | $130.93 | 2021-2022 | |
| Amgen INC. | $124.48 | 2021-2023 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $101.96 | 2021-2022 | |
| Amarin Pharma, INC. | $101.19 | 2021 | |
| Abbott Laboratories | $99.86 | 2023 | Freestyle Libre 3 |
| Vivus LLC | $92.91 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $72.71 | 2023-2024 | Onzetra Xsail, Contrave, Nexletol |
| Next Science LLC | $69.95 | 2024 | Blastx, Xperience, Surgx |
| Merck Sharp & Dohme LLC | $65.52 | 2021 | |
| Madrigal Pharmaceuticals | $63.32 | 2025 | Rezdiffra |
| Harmony Biosciences LLC | $59.44 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $49.19 | 2021 | |
| Horizon Therapeutics Plc | $47.26 | 2021 | |
| Exact Sciences Corporation | $42.71 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $42.27 | 2022-2023 | Ajovy |
| Corcept Therapeutics | $37.37 | 2023 | Korlym |
| Idorsia Pharmaceuticals US INC | $32.21 | 2023-2024 | Quviviq |
| Verity Pharmaceuticals INC. | $31.11 | 2025 | Tlando |
| Antares Pharma, INC. | $28.40 | 2024-2025 | Xyosted |
| Ardelyx, INC. | $25.09 | 2024 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $22.94 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.26 | 2023 | |
| Evoke Pharma, INC. | $18.35 | 2023 | Gimoti |
| Astellas Pharma US INC | $15.13 | 2021 | |
| Halozyme INC | $13.39 | 2023 | |
| Eisai INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karie Prokop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.